Huayin Health Snags ￥600M in Series C, Providing Pathology Testing Services

According to 36Kr.com, Guangzhou Huayin Medical Laboratory Center ("Huayin Health") has closed the Series C round of 600 million yuan, led by GL Capital, with participation from Guangdong Zhutou Innovation, Bank of China Group Investment, Qianhai Fund of Funds, In Capital, Everest VC, and Chongqing Sci-Tech Venture Capital. Proceeds of this financing will mainly be used for business expansion.

Previously, Huayin Health completed its US$15 million Series A financing and ￥130 million Series A financing from Sino Asia Capital and other investors. Its Series B round was led by GTJA Investment Group.

Founded in 2009 and headquartered in Guangzhou, China, Huayin Health is a comprehensive medical group engaged in medical inspection and testing services, and high-tech development. Up to now, the group provides clinical services for more than 2,000 hospitals in 27 provinces and regions in China, with five provincial laboratories and an annual diagnostic sample volume of more than 8.5 million.

Huayin Health has cooperated with colleges and universities. In 2010, the company reached strategic cooperation with Southern Medical University, and established the Huayin Pathological Diagnosis Center with Southern Medical University in 2011. In addition, Huayin Health also carries out transnational cooperation in pathology, and has built cooperation in remote pathological diagnosis and scientific research with the University of Pennsylvania in the US, the University of Bradford in the UK, and other international famous universities.

For business expansion, Huayin Health is striving to promote in two directions. One is to improve the customer service and technological development in the field of pathology, and to take actions in talent cultivation, scientific research cooperation and pathological AI. The other is to expand the layout in the field of diagnosis based on pathology.

Established in 2010, GL Capital is a healthcare-focused, value-driven investment management group in China. Since inception, GL Capital has developed a reputation as the partner-of-choice for leading healthcare companies and demonstrated capability to add value to its portfolio companies.

In December 1984, BOCG Investment was incorporated in Hong Kong as a wholly-owned subsidiary of BOC. BOCG Investment has invested in a great number of large infrastructures and major projects in Hong Kong, Macao, Mainland China and overseas, covering such sectors as real estate, industry, energy, transportation, media, hotels and finance, etc.